Ovarian cancer drug will cost HAs millions

Health authorities will have to find millions of pounds to fund cancer drugs after the National Institute for Clinical Excellence backed the use of paclitaxel to treat patients with ovarian cancer.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here